Breast tumor stroma: A driving force in the development of resistance to therapies-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Breast tumor stroma: A driving force in the development of resistance to therapies

Published:2017-01-02 Issue:3 Volume:89 Page:309-318
ISSN:1747-0277
Container-title:Chemical Biology & Drug Design
language:en
Short-container-title:Chem Biol Drug Des

Author:

Majidinia Maryam¹²,Yousefi Bahman³⁴⁵

Affiliation:

1. Department of Clinical Biochemistry; Faculty of Medicine; Urmia University Medical Sciences; Urmia Iran

2. Stem Cell Research Center; Tabriz University of Medical Sciences; Tabriz Iran

3. Immunology Research Center; Tabriz University of Medical Sciences; Tabriz Iran

4. Molecular Targeting Therapy Research Group; Faculty of Medicine; Tabriz University of Medical Sciences; Tabriz Iran

5. Department of Clinical Biochemistry and Laboratory Medicine; Faculty of Medicine; Tabriz University of Medical Sciences; Tabriz Iran

Publisher

Wiley

Subject

Molecular Medicine,Biochemistry,Drug Discovery,Pharmacology,Organic Chemistry

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cbdd.12893/fullpdf

Reference135 articles.

1. Challenges in the management of advanced, ER-positive, HER2-negative breast cancer

2. Identifying and targeting tumor-initiating cells in the treatment of breast cancer

3. The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade

4. Influence of multidrug resistance and drug transport proteins on chemotherapy drug metabolism

5. Genetic and/or non-genetic causes for inter-individual and inter-cellular variability in transporter protein expression: implications for understanding drug efficacy and toxicity

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of tumor-infiltrating lymphocytes with clinical outcomes in patients with triple-negative breast cancer receiving neoadjuvant chemotherapy: a systematic review and meta-analysis;Clinical and Translational Oncology;2024-08-18

2. Targeting breast cancer using phytoconstituents: Nanomedicine-based drug delivery;European Journal of Medicinal Chemistry Reports;2023-12

3. Paclitaxel-loaded ginsenoside Rg3 liposomes for drug-resistant cancer therapy by dual targeting of the tumor microenvironment and cancer cells;Journal of Advanced Research;2022-09

4. Mesenchymal stem cells and cancer‐associated fibroblasts as a therapeutic strategy for breast cancer;British Journal of Pharmacology;2022-05-17

5. Predicting dynamic response to neoadjuvant chemotherapy in breast cancer: a novel metabolomics approach;Molecular Oncology;2022-04-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3